Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022418 · ClinicalTrials.gov registry record · Phase 2
Formoterol in Diabetes
A Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07022418: Recruiting Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies, sponsored by Medical University of South Carolina.
NCT07022418 is a Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 120 participants, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07022418, a Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.
Primary Outcome
The primary measures of feasibility will be study refusal rate and adherence during the 36-week treatment. Refusal rate will be the percentage of individuals who are offered the opportunity to enroll but choose not to accept it. Adherence will be defined as the proportion of doses taken during the 36-week treatment period. For patients who fail to complete the study, adherence will be estimated as the number of doses they report taking for visits at which they are present over the total number o
Conditions Studied
Interventions
- DRUG Formoterol furmarate (20 μg)
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT07022418 shows while recruiting
NCT07022418 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Formoterol furmarate (20 μg) is the first listed.
NCT07022418 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT07022418 about?
NCT07022418 is a clinical study titled "Formoterol in Diabetes". The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment on...
What is the current status of trial NCT07022418?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-12-01. Estimated completion is 2027-11.
What conditions does trial NCT07022418 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Diabetic Nephropathies.
What interventions are being tested in trial NCT07022418?
The interventions under investigation include: Formoterol furmarate (20 μg) (DRUG).
Who is sponsoring clinical trial NCT07022418?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022418 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07022418's enrollment target sits among peer trials
120 10th of 23 higher than 13 of 23 other Diabetic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
COMPLETED · Phase 2
-
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI